LXRX ($1.77)- Currently I am down about (-7.56%)- Lexicon completed enrollment of patients in the placebo-controlled, expansion portion of the trial and expects to report top-line results near the end of the first quarter of 2014.
I might be doing an average down here with LXRX. I try not to fight the market. Take what the market is giving for now and average down.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.